Exclusive: FDA's cancer drug regulator and Replimune's rejection

Also: Screening guideline change led to more colorectal cancers being detected early in younger adults

August 5, 2025 Check out STAT+

Sponsored By

Deal alert: Unlock unlimited access to award-winning journalism, premium data tools, event discounts, and more. Use code JUNE50 to save 50% off a STAT+ annual subscription now.

FDA STAT+ | FDA's top cancer drug regulator played key role in rejection of Replimune therapy, officials say Agency officials said Vinay Prasad, who was criticized before his ouster for taking a hard line in reviews, did not have substantive role in debate. By Adam Feuerstein Screening guideline change led to more colorectal cancers being detected early in younger adults With colorectal cancer rising, federal panel cut the screening age to 45. More cancers found early, more lives saved, two new studies say By Angus Chen and Veronica Paulus STAT+ | Opinion: I've spent 30 years trying to harness AI to fight cancer. I'm dismayed by the AI pseudo-revolution Terrified of slipping in rankings, hospitals are rushing to adopt AI — often without fully grasping their limitations, ethical implications, or efficacy. By Hamid Tizhoosh Sandy Huffaker for STAT STAT+ | Uncertainty clouds the San Diego biotech hub, with jobs and capital scarce San Diego's biotech hub faces rising layoffs, vacant lab space, and dwindling funding, but local leaders say region is poised for a rebound By Jonathan Wosen

More around STAT

---

In case you missed it The murkiness of drug companies' price transparency reports. Carefully curated drug pricing reports can manipulate the reality of how much Americans spend on prescription drugs, STAT Bill Gates says rising anti-vaccine sentiment in U.S. will exact heavy toll overseas, STAT How surgeons build a new bladder for cancer patients like Deion Sanders, NPR For some, a new approach to infertility is revolutionary. For others, it's old wine in a new bottle, STAT An AI tool to help diagnose dementia leverages the Mayo Clinic's expertise — and its data, STAT

---

Check out more exclusive coverage with a STAT+ subscription Read premium in-depth biotech, pharma, policy, and life science coverage and analysis with all of our STAT+ articles.

---

Enjoying Cancer Briefing? Tell us about your experience Continue reading the latest health & science news with the STAT app Download on the App Store or get it on Google Play

STAT, 1 Exchange Place, Boston, MA ©2025, All Rights Reserved. I no longer wish to receive STAT emails

Update Newsletter Preferences     •    Contact Us     •    Advertise with Us     •    View in Browser